MRK · 10-Q · 2026Q2 · Full report

Clinical Pipeline Developments

Merck & Co., Inc. · 2026-08-07 · Importance 61 · Surprise 42

Tulisokibart met the primary endpoint of clinical remission in the Phase 3 ATLAS-UC induction-only study in patients with moderately to severely active ulcerative colitis and also met key secondary endpoints. A Phase 2 hidradenitis suppurativa study met its primary and key secondary endpoints, while a Phase 2 systemic-sclerosis-associated interstitial-lung-disease study failed its primary endpoint and will be discontinued. Merck is continuing additional Phase 3 and Phase 2 tulisokibart studies in immune-mediated inflammatory diseases and plans to present results at an upcoming scientific congress.